Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.

Cost-Benefit Analysis Humans Multiple Sclerosis / therapy Quality-Adjusted Life Years United Kingdom
Multiple sclerosis cost-effectiveness cost-effectiveness analysis health-related quality of life quality of life quality-adjusted life-years

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 4 9 2020
medline: 17 3 2022
entrez: 4 9 2020
Statut: ppublish

Résumé

It is a familiar story. A promising multiple sclerosis (MS) treatment clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost-effectiveness. This has led to concerns about the validity of the measures typically used to quantify treatment effects in cost-effectiveness analyses and in 2012, in the United Kingdom, the National Institute for Health and Care Excellence called for an improvement in the cost-effectiveness framework for assessing MS treatments. This review describes what is meant by cost-effectiveness in health/social care funding decision-making, and usual practice for assessing treatment benefits. We detail the use of the quality-adjusted life-year (QALY) in resource allocation decisions, and set out limitations of this approach in the context of MS. We conclude by highlighting methodological and policy developments which should aid addressing these limitations.

Sections du résumé

BACKGROUND BACKGROUND
It is a familiar story. A promising multiple sclerosis (MS) treatment clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost-effectiveness. This has led to concerns about the validity of the measures typically used to quantify treatment effects in cost-effectiveness analyses and in 2012, in the United Kingdom, the National Institute for Health and Care Excellence called for an improvement in the cost-effectiveness framework for assessing MS treatments.
OBJECTIVE AND METHODS OBJECTIVE
This review describes what is meant by cost-effectiveness in health/social care funding decision-making, and usual practice for assessing treatment benefits.
RESULTS RESULTS
We detail the use of the quality-adjusted life-year (QALY) in resource allocation decisions, and set out limitations of this approach in the context of MS.
CONCLUSION CONCLUSIONS
We conclude by highlighting methodological and policy developments which should aid addressing these limitations.

Identifiants

DOI: 10.1177/1352458520954172 PMID: 32880511 PMC: PMC8894952
pubmed: 32880511
doi: 10.1177/1352458520954172
pmc: PMC8894952
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

346-351

Subventions

Organisme : Department of Health
Pays : United Kingdom

Références

Value Health. 2015 Dec;18(8):1025-36
pubmed: 26686787
Health Econ. 1999 Feb;8(1):25-39
pubmed: 10082141
Int MS J. 2006 Nov;13(3):92-9
pubmed: 17101077
Health Econ. 2015 Mar;24(3):258-69
pubmed: 24254584
Eur J Health Econ. 2006 Sep;7 Suppl 2:S86-95
pubmed: 17310338
Appl Health Econ Health Policy. 2013 Aug;11(4):331-41
pubmed: 23637055
Health Econ. 2010 Feb;19(2):125-9
pubmed: 20049843
Value Health. 2018 Nov;21(11):1338-1345
pubmed: 30442282
BMJ. 2010 Jun 03;340:c1786
pubmed: 20522655
Health Technol Assess. 2012;16(16):1-166
pubmed: 22459668
Appl Health Econ Health Policy. 2015 Dec;13(6):557-65
pubmed: 26324402
Qual Life Res. 2001;10(1):49-55; discussion 57-8
pubmed: 11508475
Value Health. 2020 Feb;23(2):242-250
pubmed: 32113630
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Value Health. 2015 Dec;18(8):1016-24
pubmed: 26686786
Pharmacoeconomics. 2014 Aug;32(8):759-73
pubmed: 24846760
Eur J Health Econ. 2006 Sep;7 Suppl 2:S75-85
pubmed: 17310342
J Health Econ. 2002 Mar;21(2):271-92
pubmed: 11939242
Health Technol Assess. 2012 Jul;16(32):1-114
pubmed: 22832015
Health Econ. 2015 Oct;24(10):1256-1271
pubmed: 25251336
Value Health. 2012 May;15(3):504-13
pubmed: 22583461
Health Technol Assess. 2009 Feb;13(12):iii, ix-x, 1-177
pubmed: 19216837
Value Health. 2007 Jan-Feb;10(1):54-60
pubmed: 17261116
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Mult Scler. 2019 Oct;25(11):1496-1505
pubmed: 30070613

Auteurs

Annie Hawton (A)

Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK/NIHR Applied Research Collaboration (ARC) South West Peninsula, University of Exeter Medical School, University of Exeter, Exeter, UK.
ORCID: 0000-0002-1336-5899

Elizabeth Goodwin (E)

Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK.

Kate Boddy (K)

NIHR Applied Research Collaboration (ARC) South West Peninsula, University of Exeter Medical School, University of Exeter, Exeter, UK.

Jennifer Freeman (J)

School of Health Professions, Faculty of Health, University of Plymouth, Plymouth, UK.

Sarah Thomas (S)

Faculty of Health and Social Sciences, Bournemouth University, Bournemouth, UK.

Jeremy Chataway (J)

Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK/National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.

Colin Green (C)

Health Economics Group, University of Exeter Medical School, University of Exeter, Exeter, UK/Collaboration (ARC) South West Peninsula, University of Exeter Medical School, University of Exeter, Exeter, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Organisations et économie des soins de santé › Économie › Coûts et analyse des coûts › Analyse coût-bénéfice › Measuring the cost-effectiveness of treatments...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Measuring the cost-effectiveness of treatments...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Measuring the cost-effectiveness of treatments...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Espérance de vie › Années de vie ajustées sur la qualité › Measuring the cost-effectiveness of treatments...
questionsmedicales.fr › Régions géographiques › Europe › Royaume-Uni › Measuring the cost-effectiveness of treatments...